Ultragenyx Pharmaceutical Inc. (RARE) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Ultragenyx Pharmaceutical Inc. (RARE): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 53/100 — a percentile rank of Ultragenyx Pharmaceutical Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.
| Market cap | $1.5B |
| P / S | 2.1× |
| EV / EBITDA | -2.7× |
| Gross margin | 83.1% |
| Operating margin | -73.6% |
| Net margin | -81.7% |
| Return on equity | 201.4% |
| ROIC | 130.0% |
| Revenue growth | 17.5% |
| Debt / equity | -0.0× |
| Dividend yield | 0.0% |
Is Ultragenyx Pharmaceutical Inc. overvalued? P/S looks undervalued vs its 5-year range.
Independent of the events above — derived from Ultragenyx Pharmaceutical Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact